PF-Atlas › Treatments › Ruxolitinib

Ruxolitinib

Blocks SASP cytokine signaling (IL-6, IL-8) without killing senescent cells

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase I/II
Evidence level
Level 2 (Repositioning)
Mechanism class
Blocks SASP cytokine signaling (IL-6, IL-8) without killing senescent cells
Timeline
2 years
Risk profile
Low-Medium
Developer
Incyte / Multiple
Key researchers
Multiple

Overview

FDA-approved for GVHD. Blocks JAK1/2 downstream of SASP. Seno-morphic approach. Generic available.

How Ruxolitinib fits into IPF treatment

Ruxolitinib is classified as Level 2 (Repositioning) at the Phase I/II stage. Explore how it compares to other options and where it sits in the development pipeline:

Ruxolitinib drug profileBlocks SASP cytokine signaling (IL-6, IL-8) without killing senescent cellsClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Ruxolitinib for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.